Vivos Inc. and Exubrion Therapeutics Enhance Collaboration for Animal Care

Vivos Inc. and Exubrion Therapeutics Unite for Animal Health Innovations

In a significant development for companion animal healthcare, Vivos Inc. (OTCQB: RDGL) has announced an enhanced strategic collaboration with Exubrion Therapeutics. This partnership aims to harness targeted radioactive isotope technology, paving the way for innovative treatments addressing multiple health conditions in pets.

Broadening Collaborative Efforts

The agreement between Vivos and Exubrion marks a pivotal expansion of their collaborative efforts. The companies are focusing on several essential areas, including nurturing shared clinic relationships, streamlining licensing processes, and optimizing manufacturing capabilities. These initiatives are a natural progression from their previous work, which included device classification and the development of training modules for clinicians.

Complementary Strengths for Greater Impact

“Our companies complement one another exceptionally well,” stated Dr. Michael K. Korenko, the Chief Executive Officer of Vivos Inc. He emphasized how Exubrion’s specialization in managing osteoarthritis pain in animals, alongside Vivos’s focus on cancer therapies, enables a partnership that enhances their respective markets without conflicting competition.

Dr. Korenko also noted the importance of continuous improvement. He stated, “With only a limited number of companies exploring therapeutic applications of radioactive isotopes, collaborative innovation is vital for advancing this essential medical field.”

Shared Vision for Progress

Jennifer Kirk, Chief Executive Officer of Exubrion Therapeutics, expressed her enthusiasm regarding this partnership. “I’m excited to collaborate with the Vivos team to help further this important work,” she remarked. Together, they aim to quicken the pace of progress in the application of radioisotopes, creating a versatile platform with broad potential in veterinary medicine.

About Vivos Inc.

Vivos Inc. is recognized as a pioneering radiotherapeutic company that develops innovative isotope-based therapies for the treatment of cancer and other medical applications. The company’s flagship technologies include RadioGel for human use and IsoPet for veterinary patients. Both products are meticulously designed to ensure targeted delivery of therapeutic radiation to tumor sites while protecting the surrounding healthy tissue from exposure.

About Exubrion Therapeutics

Exubrion Therapeutics is dedicated to enhancing the quality of life for companion animals through innovative radiotherapeutic solutions. The company’s lead product, Synovetin OA, offers a minimally invasive approach to osteoarthritis treatment, targeting the core issues of the disease and providing extended relief from joint pain.

Meet the Team

Dr. Michael K. Korenko leads Vivos Inc. as CEO, where he drives the company’s strategic vision and operations. For inquiries, he can be reached via email at MKorenko@RadioGel.com. Vivos Inc. invites you to stay connected on X (formerly Twitter) @VivosIncUSA for the latest updates on their advancements in the field.

Frequently Asked Questions

What is the main focus of Vivos Inc. and Exubrion Therapeutics' collaboration?

The collaboration primarily focuses on utilizing targeted radioactive isotope technology to develop treatments for various conditions affecting companion animals.

What are the key technologies developed by Vivos Inc.?

Vivos Inc. has developed RadioGel for human applications and IsoPet specifically for veterinary use, both aimed at delivering localized therapeutic radiation.

How does Exubrion Therapeutics contribute to animal health?

Exubrion Therapeutics focuses on improving the lives of companion animals through innovative therapies, particularly in managing osteoarthritis with their product Synovetin OA.

Who leads Vivos Inc.?

Dr. Michael K. Korenko serves as the Chief Executive Officer of Vivos Inc., overseeing the strategic direction and innovation initiatives of the company.

How can I learn more about Vivos Inc.'s products?

For more information on their groundbreaking treatments and technology, you can visit Vivos Inc.'s official website at www.VivosInc.com.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.